Nikolaos Tezapsidis, PhD President & CEO and Chairman of the Board   Arthur Klausner, MBA         A seasoned life sciences venture capitalist, Klausner has a total of 18 years of experience at Domain Associates (1990-2004) and Pappas Ventures (2005-2009).  During that time, he has been involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies.  Klausner has been a board member at Santarus (IPO in 2004, Nasdaq: SNTS), X-Ceptor (acquired by Exelixis in 2004), Altea Therapeutics, CeNeRx BioPharma, Gentis, and Syndax Pharmaceuticals, and a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005), Cerexa (acquired by Forest Laboratories in 2007), and Optherion.         Klausner began his venture capital career after earning an M.B.A. at the Stanford University Graduate School of Business.  While attending business school, he completed summer internships emphasizing corporate planning and market research functions at ImClone Systems and Neurogen, two start‑up biopharmaceutical companies that subsequently went public.  Previously, Klausner had spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology.  He has also performed consulting projects for the U.S. Office of Technology Assessment, Arthur D. Little Decision Resources, and a range of pharmaceutical and biotechnology companies.  His undergraduate degree in Biology is from Princeton University.      Eugene Oliva, MBA CFO    George Perry, PhD            Dr. George Perry obtained his bachelor of arts in zoology with high honors from the University of California at Santa Barbara in 1974 and completed his Ph.D. in marine biology from the Scripps Institution of Oceanography, University of California, San Diego in 1979.  After postdoctoral studies in cell biology at Baylor College of Medicine, Dr. Perry joined the faculty of Case Western Reserve University in 1982 as an Assistant Professor and served as a Professor in the Departments of Pathology and Neurosciences and as Interim-Chair of the Department of Pathology.  Additionally, he was named Fellow by the American Association for the Advancement of Science in 1998 and is an internationally known invited lecturer and has numerous papers, presentations and publications.  Dr. Perry is currently Dean of the College of Sciences at The University of Texas at San Antonio.             Dr. Perry’s studies are focused on the mechanism of formation and physiological consequences of the cytopathology of Alzheimer disease.  Dr. Perry’s group has shown that oxidative damage is the initial cytopathological abnormality in Alzheimer disease.  The lab is working to determine the sequence of events leading to neuronal oxidative damage and the source of the increased oxygen radicals.  Current studies focus on three issues: (i) the metabolic basis for the mitochondrial damage restricted to vulnerable neurons; (ii) the consequences of RNA oxidation on protein synthesis rate and fidelity; and (iii) role of phosphorylation in controlling oxidative adduction. Perry is among the top dozen most cited investigators studying AD/oxidative stress (over 2000 citations per year), and among the top 50 neuroscientists in the world.             Perry is a Fellow of the American Association for the Advancement of Sciences, recently won the Denham Harmon Lifetime Achievement Award (discoverer of the Free Radical Theory of Aging) from the American Association for Aging, and currently holds the Zenith Award from the Alzheimer Association.   James Harris, MBA         Mr Harris is CEO of Healthcare Economics LLC and co-founder of AS Biotech AG.  Prior to this he served as Vice President at Dragon Pharmaceuticals, Inc. where he was instrumental in the launch and successful market penetration of rh-Erythropoietin (“EPO") in non patented markets and is very well experienced in in-out licensing and business development internationally.  Before joining Dragon Mr. Harris was at Amgen where he held various positions of increasing responsibility.  He contributed in the product launches of EPO (Epogen®), GCSF (Neupogen®) at Amgen, and Intravenous Immune Globulin, IVIG (Gamimune®) at Bayer AG.  Mr. Harris has participated extensively as a featured speaker at medical meetings as well as authoring “GCSF and Bioequivalence: “The Emergence of Healthcare Economics” WILEY-VCH, Weinheim, Germany and “Marketing and Globalizing Biosimilars” Journal of Generic Medicines, London, UK.  He has served as the Assistant Area Chair Department of Graduate Business and Management at the University of Phoenix. Mr. Harris obtained a B.A. in Political Science from Wright State University and an M.B.A. in Finance from Long Island University.